Development of APREMILAST Tablet (Innovator name: OTEZLA) 10, 20 and 30MG

CELGENE CORP has NDA approval of OTEZLA tablet indicated for the treatment of adult patients with active psoriatic arthritis on March 21, 2014.

First To File Date for Aprmilast Tablet is March 21, 2018 which is NCE-1 (NCE Exclusivity Expiration is March 21, 2019).

OTEZLA tablet has $471.7 Million sale in year 2015. 

Excipients used in OTEZLA tablets are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate to manufacure core tablet.

Explore more about APREMILAST Tablet development by following below link...

Develop Apremilast Tablet